Montelukast and budesonide combination for children with chronic cough-variant asthma

Abstract

This study investigated the effectiveness and safety of montelukast combined budesonide (MCB) treatment for children with chronic cough-variant asthma (CCVA).In total, 82 cases of children with CCVA, aged 4 to 11 years were included in this study. All cases received either MCB or budesonide alone between May 2015 and April 2017. The primary outcome was lung function, measured by the peak expiratory flow rates (PEFRs) and forced expiratory volume in 1 second (FEV1). The secondary outcome was measured by the clinical assessment score. Furthermore, adverse events (AEs) were also recorded in this study. All outcomes were measured after 8-week treatment.After 8-week treatment, MCB showed greater effectiveness than did budesonide alone in improving the lung function, measured by PEFR V1 (P = .02), and FEV1 (P < .01). Similarly, the clinical assessment score also demonstrated significant difference between the 2 groups (P < .05). In addition, no serious AEs occurred in both groups.The results of this study demonstrate that the effectiveness of MCB is superior to budesonide alone in the treatment of children with CCVA.

Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum

“…Loratadine, a piperidine antihistamine that antagonizes peripheral H1 receptors over a long time efficiently, can greatly improve the airway hyperresponsiveness, inhibit the degranulation of eosinophils and mast cells, and reduce the release of leukotrienes (22). The good complementarity and synergistic therapeutic effects of montelukast sodium combined with budesonide or loratadine in cough variant asthma have been reported in many studies (11,12). According to the results of this study, both methods of drug treatments had a good therapeutic effect with an effective rate of >90%, and improved eosinophil granulocyte level and IgE level, similarly to previous research results (11,12).…”

“…The good complementarity and synergistic therapeutic effects of montelukast sodium combined with budesonide or loratadine in cough variant asthma have been reported in many studies (11,12). According to the results of this study, both methods of drug treatments had a good therapeutic effect with an effective rate of >90%, and improved eosinophil granulocyte level and IgE level, similarly to previous research results (11,12). The two methods of drug treatment both had similar efficacy in improving the lung function indexes and the inflammation symptoms, slight adverse reactions, and not statistically different incidence rates of recurrence, proving that montelukast sodium combined with budesonide or loratadine were equivalent in the treatment efficacy of cough variant asthma.…”

“…The evaluation of efficacy was divided into four degrees: Complete recovery, significant efficacy, certain efficacy, and no efficacy. Complete recovery means that the symptoms of cough and asthma totally disappeared with no complications, significant efficacy means that the symptoms of cough and asthma were basically improved, and the incidence rate of complications was ≤5%; certain efficacy means that the symptoms of cough and asthma were partly improved, and the incidence rate of complications was ≤10%; no efficacy refers to no improvement of symptoms and even worsen symptoms (12).…”

“…Loratadine, a piperidine antihistamine commonly used in the treatment of allergic diseases, has also been used in recent years to treat cough variant asthma (10). In some related studies, montelukast sodium combined with budesonide or loratadine has been proven to have a good efficacy in the treatment of cough variant asthma (11,12). However, few comparative studies have been made on the efficacy of these three drugs, montelukast sodium, budesonide and loratadine in cough variant asthma.…”

lncRNA PCGEM1 strengthens anti-inflammatory and lung protective effects of montelukast sodium in children with cough-variant asthma

“…Montelukast sodium, a potent leukotriene 1 receptor antagonist, has been shown to control chronic non-productive cough effectively in CVA (7). Montelukast sodium has also been applied alone or combined with other anti-asthmatic drugs like budesonide, which is superior to budesonide alone for treating the children with chronic CVA (8). However, little attention has been paid to the mechanisms underlying the therapeutic effect of montelukast sodium on asthma and CVA.…”